Therefore, it is necessary to monitor both CD33 and NKG2D expression levels on ex vivo expanded NK cells and leukemic blasts isolated from PB of AML patients to improved therapeutic benefit. This evidence concerns the gene CD33 and acute myeloid leukemia.